iBio, Inc. (NYSE AMEX: IBIO) today announced the engagement of CBR International Corporation (CBR) for strategic regulatory and clinical services to advance iBio’s Orphan Drug designated, plant-produced human alpha galactosidase A (“α-Gal A”) enzyme candidate for development as a therapeutic option for patients with Fabry disease.

“We expect this engagement to significantly accelerate our path to the clinic for this important product application of our platform technology,” said Robert Erwin, President of iBio. “CBR managed the successful application for Orphan Drug designation of plant-made α-Gal A, and has substantial experience in this field. They will join the team comprising our regular research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology and our manufacturing partner, Kentucky Bioprocessing, LLC.”

This Fabry disease therapeutic program is part of iBio’s broader program to bring forward approximately ten more candidate proteins for commercialization as “biosimilar” or “biobetter” therapeutic products. iBio intends to advance these candidates at least to a point sufficient to demonstrate the advantages of making them using the iBioLaunch™ platform technology and then enter into collaborative arrangements with industry partners. iBio already has demonstrated the applicability of its platform technology to most therapeutic protein classes, ranging from cytokines and growth factors to enzymes and antibodies.

Dr. Jeanne Novak, President and CEO of CBR commented, “Enzyme replacement therapy has been constrained by production limitations, interruptions and treatment cost. Patients with Fabry disease who do not receive enzyme replacement therapy are at increased risk of strokes, heart attack, heart disease, and renal failure. iBio’s innovative platform technology promises to add greater capacity for the supply of therapeutic protein biologics so that α-Gal A and other critical enzymes can be made available to more patients who need them in the future. We are confident that CBR’s clinical and regulatory expertise and extensive prior experience with α-Gal A will help expedite the development of iBio’s Fabry disease product program.”

Current estimates indicate a patient population affected by Fabry Disease of approximately 8,000 to 10,000. Current therapies in use are estimated to cost more than $200,000 per patient year.

About Fabry Disease

Fabry disease is caused by the inherited deficiency of the enzyme, alpha galactosidase A, whose function is to break down a fatty substance called globotriaosylceramide. The defective gene is carried on the X chromosome, and men with the defect tend to experience worse symptoms than women who carry one copy of the defective gene. However, many women who are heterozygous for the defect are symptomatic and are frequently under-treated. Symptoms of the disease typically begin in childhood and include pain in the hands and feet, angiokeratomas, and changes in the cornea. The disease is progressive and symptoms of kidney, heart and neurological damage may occur in young adulthood. Enzyme replacement therapy with recombinant human alpha-galactosidase A has been proven clinically beneficial in the reduction of disease symptoms.

About iBio, Inc.

iBio, Inc. is a biotechnology company offering its proprietary, transformative iBioLaunch technology platform for the production of biologics including therapeutic proteins and vaccines. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. Advantages include significantly lower capital and process costs. Additionally, the technology is ideally suited for complex proteins and for applications where speed, scalability, and surge capacity are important. The iBioLaunch technology was developed for iBio by the not-for-profit Fraunhofer USA Center for Molecular Biotechnology (FCMB) during the past eight years to overcome the inadequacies of existing technologies. iBio owns the intellectual property and technology developed at FCMB, and continues to sponsor development and application of the technology for biological applications in human health. Further information is available at: www.ibioinc.com.

About CBR International

CBR International Corporation is a global, full-service product, clinical, and regulatory company dedicated to providing comprehensive development services to the biotechnology, pharmaceutical, and device industries around the world. The CBR staff is experienced in a wide range of indications for drugs, novel antibodies, recombinant protein therapeutics, small molecules, vaccines, cell therapy, device and combination products throughout all phases of program development (Phase I – IV) and commercialization.

Forward-Looking Statements

Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the Company's reports filed with the U.S. Securities and Exchange Commission.

Copyright Business Wire 2010